Terms: = Prostate cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Treatment
3094 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
3. Breakthrough electroneutron multi-response miniature dosimetry/spectrometry in medical accelerator.
Sohrabi M; Malekitakbolagh M; Nedaei HA
Sci Rep; 2024 Apr; 14(1):9557. PubMed ID: 38664481
[TBL] [Abstract] [Full Text] [Related]
4. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
5. MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score.
Pausch AM; Elsner C; Rupp NJ; Eberli D; Hötker AM
Eur J Radiol; 2024 Jun; 175():111463. PubMed ID: 38615502
[TBL] [Abstract] [Full Text] [Related]
6. High-dose-rate Brachytherapy Monotherapy in Patients With Localised prostate cancer: Dose Modelling and Optimisation Using Computer Algorithms.
Dabic-Stankovic K; Rajkovic K; Stankovic J; Marosevic G; Kolarevic G; Pavicar B
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):378-389. PubMed ID: 38584072
[TBL] [Abstract] [Full Text] [Related]
7. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
[TBL] [Abstract] [Full Text] [Related]
8. Net survival of men with localized prostate cancer after LDR brachytherapy.
Uribe-Lewis S; Uribe J; Deering C; Langley S; Higgins D; Whiting D; Metawe M; Khaksar S; Mehta S; Mikropoulos C; Otter S; Perna C; Langley S
Brachytherapy; 2024; 23(3):329-334. PubMed ID: 38538414
[TBL] [Abstract] [Full Text] [Related]
9. The design, synthesis and bioactivity evaluation of novel androgen receptor degraders based on hydrophobic tagging.
Sun Y; Wang H; Li Y; Li Z; Mao Z; Zhang M; Shao Y; Ye J; Li D; Shan L
Bioorg Chem; 2024 May; 146():107309. PubMed ID: 38537338
[TBL] [Abstract] [Full Text] [Related]
10. Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging study.
Pruis IJ; van Doormaal PJ; Balvers RK; van den Bent MJ; Harteveld AA; de Jong LC; Konijnenberg MW; Segbers M; Valkema R; Verburg FA; Smits M; Veldhuijzen van Zanten SEM
EBioMedicine; 2024 Apr; 102():105068. PubMed ID: 38518652
[TBL] [Abstract] [Full Text] [Related]
11. A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients.
Lilly MB; Wu C; Ke Y; Chen WP; Soloff AC; Armeson K; Yokoyama NN; Li X; Song L; Yuan Y; McLaren CE; Zi X
Clin Transl Med; 2024 Mar; 14(3):e1627. PubMed ID: 38515274
[TBL] [Abstract] [Full Text] [Related]
12. PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
Falkenbach F; Ambrosini F; Kachanov M; Ortner G; Maurer T; Köhler D; Beyersdorff D; Graefen M; Budäus L
World J Urol; 2024 Mar; 42(1):182. PubMed ID: 38506941
[TBL] [Abstract] [Full Text] [Related]
13. Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive prostate cancer Treated With Abiraterone Acetate.
Fukuokaya W; Mori K; Urabe F; Igarashi T; Yanagisawa T; Tsuzuki S; Honda M; Miki K; Kimura T
JAMA Netw Open; 2024 Mar; 7(3):e242467. PubMed ID: 38488793
[TBL] [Abstract] [Full Text] [Related]
14. Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up.
Jacques J; Sahki N; Meknaci É; Eschwege P; Peiffert D; Demogeot N
Brachytherapy; 2024; 23(3):301-308. PubMed ID: 38480107
[TBL] [Abstract] [Full Text] [Related]
15. Hypofractionated radiation therapy combined with androgen deprivation therapy for high-risk localized prostate cancer.
Lee TH; Pyo H; Yoo GS; Jeon SS; Seo SI; Jeong BC; Jeon HG; Sung HH; Kang M; Song W; Chung JH; Bae BK; Park W
J Med Imaging Radiat Oncol; 2024 Apr; 68(3):333-341. PubMed ID: 38477380
[TBL] [Abstract] [Full Text] [Related]
16. Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer.
Xie S; Leng J; Zhao S; Zhu L; Zhang M; Ning M; Zhao B; Kong L; Yin Y
Eur J Med Chem; 2024 Mar; 268():116301. PubMed ID: 38452727
[TBL] [Abstract] [Full Text] [Related]
17. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive prostate cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract] [Full Text] [Related]
18. Conformity of ChatGPT recommendations with the AUA/SUFU guideline on postprostatectomy urinary incontinence.
Pinto VBP; de Azevedo MF; Wroclawski ML; Gentile G; Jesus VLM; de Bessa Junior J; Nahas WC; Sacomani CAR; Sandhu JS; Gomes CM
Neurourol Urodyn; 2024 Apr; 43(4):935-941. PubMed ID: 38451040
[TBL] [Abstract] [Full Text] [Related]
19. Diagnostic value of
Guo S; Zhou C; Zhang Y; Wang D; Niu T; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1812-1819. PubMed ID: 38448374
[TBL] [Abstract] [Full Text] [Related]
20. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
[TBL] [Abstract] [Full Text] [Related]
[Next]
